What is ABUS's market cap?

$804.31M, based on the Nov 4 close of $4.06.

What is ABUS's P/E ratio?

5.3× trailing-twelve-month earnings of $153M.

Does Arbutus Biopharma pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ABUS is sold short?

24.6M shares, 15.6% of float, as of Oct 15, 2026.

What sector is ABUS in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ABUSHealthcarePharmaceuticals

Arbutus Biopharma Corporation Common Stock (ABUS)

$4.06+4.64%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$4.06▼ 9.78% in range

Nov 4, 2025Low $3.67 · High $5.22Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Arbutus Biopharma closed at $4.06 on Nov 4, up 4.64%, 22.2% below its 52-week closing high. Volume of 2.8M shares was 1.06× its 20-day average (close to normal).

Split-adjusted performance: -9.4% over one month, -8.1% over six months, -11.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.01M, down 90.6% from a year earlier, with a net margin of -512.0%.

Short interest was 24.6M shares at the Oct 15 settlement, down 27.9% from the prior report (15.6% of float, 4.3 days to cover).

Market cap$804.3M198.1M shares

Revenue · quarter$1.0M−90.6% YoY

Diluted EPS$-0.03−400.0% YoY

P/E · TTM5.3×P/S 4.4×

Net margin-512.0%Gross 100.0%

Dividend yieldNone

52-week range3.67 – 5.22−22.2% from high

Volume2.8M1.06× 20-day avg

Volatility · 60d38.2%Annualised

Short % of float15.6%4.3 days to cover

Net cash$89.5MCash $92.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −6.0%1M −9.4%3M −10.6%6M −8.1%YTD −15.6%1Y −11.4%3Y +128.1%5Y −0.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum66

Revenue growth13

Net margin29

Value (low P/E)85

Size67

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short24.6M−27.9% vs prior

Days to cover4.3Settled Oct 15

% of float15.6%

Short vol. 10d57.9%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ABUSArbutus Biopharma	$4.06	+4.64%	−8.1%	−90.6%	−512.0%	5.3	$804.3M
ANNXAnnexon	$4.33	+3.34%	−24.0%	—	—	—	$820.9M	Compare
COLLCollegium Pharmaceutical	$23.67	−0.25%	−35.2%	+6.3%	−7.5%	16.1	$770.6M	Compare
AKTSAktis Oncology	$15.20	+1.74%	−24.1%	—	−713.5%	—	$845.4M	Compare
CYRXCryoPort	$16.70	+1.52%	+31.6%	+7.7%	−20.9%	—	$845.8M	Compare
ALMSAlumis	$6.55	+0.77%	−74.3%	−37.7%	−8557.2%	—	$847.8M	Compare
ARDXArdelyx	$3.29	+8.58%	−53.7%	+15.7%	−0.6%	—	$849.4M	Compare
CRVSCorvus Pharmaceuticals	$10.57	+7.53%	−31.6%	—	—	—	$889.2M	Compare
WVEWave Life Sciences	$3.62	+1.12%	−50.3%	+72.9%	−470.5%	—	$714.0M	Compare

News about Arbutus Biopharma

All news →

No recent articles focused on Arbutus Biopharma. 2 articles mention it in passing.

Quick answers

What does Arbutus Biopharma do?: Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV).
What is ABUS's market cap?: $804.31M, based on the Nov 4 close of $4.06.
What is ABUS's P/E ratio?: 5.3× trailing-twelve-month earnings of $153M.
Does Arbutus Biopharma pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ABUS is sold short?: 24.6M shares, 15.6% of float, as of Oct 15, 2026.
What sector is ABUS in?: Healthcare, in the Pharmaceuticals industry.

About Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

HQ: Warminster, PA19 employeesListed Jul 26, 2007arbutusbio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology